Pfizer plans to explore other obesity treatments for testing. Pfizer is halting the development of its potential pill for treating obesity following an injury that happened during a clinical trial.

Pfizer discontinues danuglipron after liver injury in trial patient Lilly and Novo Nordisk shares rise after Pfizer's decision Pfizer to focus on other obesity research April 14 (Reuters) - Pfizer ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and most expensive level of clinical testing. The drugmaker said Tuesday ...

The 10-second video shows the rapper playing with a football and an ending tag, “See you at the game,” with the Pfizer logo. Additional teasers will be posted Saturday and Sunday mornings ...

Pfizer stock (NYSE: PFE) was up 5% on Tuesday, December 17, after the company announced an optimistic outlook for 2025. The company expects its revenue to be in the range of $61 billion to $64 ...

Pfizer (PFE) is exploring the sale of its hospital drugs unit, now called Pfizer Hospital, which was formed after Pfizer bought Hospira for about $17B in 2015, three people familiar with the ...

Pfizer (NYSE: PFE) is scheduled to report its Q3 2024 results on Tuesday, October 29. We expect the company to post revenue of $15.1 billion and earnings of $0.63 on a per share and adjusted basis ...

FILE - The Pfizer logo is displayed at the company's headquarters, Friday, Feb. 5, 2021, in New York. Pfizer shares sank Friday, Dec. 1, 2023, when the drugmaker announced that it was abandoning a ...

FILE - The Pfizer logo is displayed at the company's headquarters, Friday, Feb. 5, 2021, in New York. Shares of Pfizer are falling before the market opened on Monday, Oct. 16, 2023, as the company ...